Blontuvetmab  (Synonyms: AT 004; VT 007)

Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma^[1][2][3][4].

Canis IgG2 kappa

Caninized

Blontuvetmab shows partial agonist efficacy for Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) in the GTPγS binding assay using membranes from Chinese hamster ovary (CHO) cells^[4].
Blontuvetmab (10 µM) is inactive to contractile effects in mouse colon^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1608112-78-2

Liquid

Colorless to light yellow

[Blontuvetmab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG2-Vkappa-Clambda

• [1]. Mizuno T, et, al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci Rep. 2020 Jul 10;10(1):11476.  [Content Brief]

  [2]. Hu C, et al. Characterization of a potent and selective A2aR monoclonal antibody antagonist for the treatment of cancer[J]. Cancer Research, 2022, 82(12_Supplement): 3437-3437.

  [3]. Dias JNR, et al. Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. Sci Rep. 2022 Feb 17;12(1):2678.  [Content Brief]

  [4]. Ferrari F, et al. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. Eur J Pharmacol. 2016 Dec 15;793:1-13.  [Content Brief]